Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.